

## ABSTRACT

The present invention relates to novel, soluble, recombinant RANKL (Receptor Activator of Nuclear Factor -  $\kappa$ B Ligand) variant proteins which may be expressed solubly in *E. coli*, variants that have  
5 substantially reduced binding to OPG, variants that act as RANKL antagonists, and methods for generating the same.